%0 Journal Article
%T 英夫利昔单抗治疗IVIG无反应型川崎病的进展<br>Progress in the Treatment of IVIG-Resistant Kawasaki Disease with Infliximab
%A 宋木雯
%A 余更生
%J Asian Case Reports in Pediatrics
%P 18-22
%@ 2328-0441
%D 2020
%I Hans Publishing
%R 10.12677/ACRP.2020.82004
%X <div style=\"text-align:justify;\">
	川崎病(Kawasaki disease, KD)是一种以全身性血管炎为特征的急性自限性疾病，病因尚不清楚，静脉注射丙种球蛋白(intravenous immunoglobulin, IVIG)联合阿司匹林治疗可缓解川崎病的炎症反应，但仍有部分患者对治疗无反应，本文主要针对英夫利昔单抗在IVIG无反应型川崎病中的应用进行综述。<br />
Kawasaki disease is an acute self-limited disease characterized by systemic vasculitis; etiology is unclear; intravenous immunoglobulin and aspirin therapy can alleviate the inflammation of Kawasaki disease, but there are still some patients do not respond to treatment. This review focuses on the application of infliximab in IVIG reactive Kawasaki disease.
</div>
%K IVIG无反应型川崎病，英夫利昔单抗，综述<br>IVIG-Resistant Kawasaki Disease
%K Infliximab
%K Reviews
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=35600